INT244386
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
This data indicate a significant increase in the expression of NKCC1 and, conversely, a decrease in KCC2 expression at the epicenter on day 14 post-SCI (prior to the chronic phase of post-SCI neuropathic hyperalgesia). | |||||||||||||||
| |||||||||||||||
|
For DRG neurons, the expression of NKCC1 is well documented [13,22], while the expression of KCC2 is controversial [23,24]. | |||||||||||||||
| |||||||||||||||
|
The effect of the mediators is consistent with increased Cl- accumulation, as NKCC1 expression is enhanced, while KCC2 expression is attenuated.
| |||||||||||||||
| |||||||||||||||
|
We find that inflammatory mediators cause an increase of Cl- levels in DRG neurons which correlates with enhanced NKCC1 expression and decreased KCC2 expression.
| |||||||||||||||
| |||||||||||||||
|
After 3 hours of treatment, the efficiency of Cl- accumulation is further enhanced through upregulation of NKCC1 expression and reduced expression of the K+-Cl- co-transporter KCC2. | |||||||||||||||
| |||||||||||||||
|
Changes of NKCC1 and KCC2 in hyperalgesia rats following SCI | |||||||||||||||
| |||||||||||||||
|
Moreover, an increase in NKCC1 protein expression occurred in the lesion epicenter of the spinal cord during day 214 post-SCI and peaked on day 14 post-SCI (p < 0.05). | |||||||||||||||
| |||||||||||||||
|
After intra-colonic capsaicin injection in mice, NKCC1 plasma membrane expression and phosphorylation are increased in the dorsal spinal cord, although it is unknown whether it is accompanied with KCC2 down-regulation [16]. | |||||||||||||||
| |||||||||||||||
|
Furthermore, they are sufficient to trigger the switch as shown with in vitro or in vivo antisense inhibition [124, 261, 302,351], overexpression of KCC2 or NKCC1 [6, 39, 165] or pharmacological inhibitors of CCCs [333]. | |||||||||||||||
| |||||||||||||||
|
In the present study, we demonstrated an increase of BSC-1 protein expression in CRF rats treated with vehicle compared with sham-operated rats, and this was consistent with our previous study demonstrating an increase of density per nephron of BSC-1 in CRF rats (although the previous study demonstrated unchanged protein expression of BSC-1 between CRF and sham-operated rats (6)). | |||||||||||||||
| |||||||||||||||
|
This could induce an increased loading of NaCl and fluid into the TAL, thereby increasing the BSC-1 expression. | |||||||||||||||
| |||||||||||||||
|
The decreased AQP2 expression in CRF rats was not altered in response to candesartan treatment; 3) Candesartan treatment was associated with decreased NHE3 and TSC expression in CRF, which could be due to the Ang II AT1 receptor blockade and/or decreased aldosterone levels; and 4) BSC-1 expression was increased in both CRF groups and the increased expression of BSC-1 was more prominent in candesartan-treated CRF rats compared with vehicle-treated CRF rats. | |||||||||||||||
| |||||||||||||||
|
Semi-quantitative immunoblotting of whole kidney protein samples from CRF rats and sham-operated rats demonstrated that CRF rats, both vehicle-treated and candesartan-treated, had significantly increased BSC-1 expression, compared with sham-operated controls (Fig. 4, Table 2). | |||||||||||||||
| |||||||||||||||
|
Kidney expression of BSC-1 was increased in CRF rats both vehicle-treated (CRF-V) and candesartan-treated (CRF-C) | |||||||||||||||
| |||||||||||||||
|
The decreased AQP2 expression in CRF rats was not altered in response to candesartan treatment; 3) Candesartan treatment was associated with decreased NHE3 and TSC expression in CRF, which could be due to the Ang II AT1 receptor blockade and/or decreased aldosterone levels; and 4) BSC-1 expression was increased in both CRF groups and the increased expression of BSC-1 was more prominent in candesartan-treated CRF rats compared with vehicle-treated CRF rats. | |||||||||||||||
| |||||||||||||||
|
Moreover, candesartan treatment in CRF rats significantly increased whole kidney BSC-1 expression (611±126% of sham-operated control level), compared with CRF rats treated with vehicle only (289±63% of sham-operated control level, p<0.05, Fig. 4, Table 2).
| |||||||||||||||
| |||||||||||||||
|
We have previously demonstrated that chronic infusion of supraphysiological doses of AngII in normal rats was associated with significantly increased abundance and apical expression level of the Na-H exchanger NHE3 and Na-K-2Cl cotransporter BSC-1 in medullary thick ascending limbs (mTAL), whereas Na,K-ATPase and electroneutral Na-HCO3 cotransporter (NBCn1) levels remained unchanged (10). | |||||||||||||||
| |||||||||||||||
|
Moreover, candesartan treatment potentiated the upregulation of BSC-1 protein expression in CRF rats, and this is also compatible with the view that BSC-1 expression is regulated by the prolonged increase in the NaCl load delivered to the TAL due to both hyperfiltration and altered expression in the proximal tubule sodium transporters in remnant kidneys. | |||||||||||||||
| |||||||||||||||
|
Semiquantitative immunoblotting demonstrated decreased AQP2 expression in both CRF-C (54% of control levels) and CRF-V (57%), whereas BSC-1 expression was increased in both CRF groups. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.